Is DERMIDEX 2%W/W CREAM registered in Malawi?

DERMIDEX 2%W/W CREAM is recorded with registration status “Registered” in Malawi, registration number PMPB/PL316/22, based on PMRA data.

What is the active ingredient in DERMIDEX 2%W/W CREAM?

DERMIDEX 2%W/W CREAM contains MICONAZOLE NITRATE BP, dosage form CREAM.

Registered Malawi · PMRA

DERMIDEX 2%W/W CREAM

MICONAZOLE NITRATE BP

PMPB/PL316/22 CREAM

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.

PMPB/PL316/22

Registration date

28/11/2008

Expiry date

30/06/2014

Status

Registered

Active ingredient

MICONAZOLE NITRATE BP

Dosage form

CREAM

Strength

Pack size

Therapeutic class

Manufacturer / MAH

Applicant / LTR

Country of origin

Source: Pharmacy and Medicines Regulatory Authority · fetched 2026-04-21 17:37:40 · updated 2026-09-29 04:33:05

Drug Interactions

Check interactions

Severe (5)

Antihistamines,non-Sedating - increases exposure

Miconazole is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid.

Severe Theoretical

Ergometrine - increases exposure

Miconazoleispredictedtoincreasetheexposureto ergometrine.Avoid.oTheoretical

Severe Theoretical

Ergotamine - increases exposure

Miconazoleispredictedtoincreasetheexposureto ergotamine.Avoid.oTheoretical

Severe Theoretical

Mizolastine - increases exposure

Miconazole is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid.

Severe Theoretical

Oral Benzodiazepines - increases exposure

Miconazole is predicted to increase the exposure to oral benzodiazepines (midazolam). Avoid.

Severe Theoretical

Moderate (33)

Alfentanil - increases exposure

Miconazole is predicted to increase the exposure to opioids (alfentanil). Use with caution and adjust dose.

Moderate Theoretical

Alkylating Agents - increases concentration

Miconazole is predicted to increase the concentration of alkylating agents (busulfan). Use with caution and adjust dose.

Moderate Theoretical

Alprazolam - increases exposure

Miconazole is predicted to increase the exposure to benzodiazepines (alprazolam). Use with caution and adjust dose.

Moderate Theoretical

Amlodipine - increases exposure

Miconazole is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, verapamil). Use with caution and a

Moderate Theoretical

Antiarrhythmics - increases exposure

Miconazole is predicted to increase the exposure to antiarrhythmics (disopyramide). Use with caution and adjust dose.

Moderate Theoretical

Unknown (6)

Aminoglycosides - decreases exposure

Miconazole potentially decreases the exposure to aminoglycosides (tobramycin).

Unknown Anecdotal

Cobimetinib - increases exposure

Miconazoleispredictedtoincreasetheexposureto cobimetinib.rTheoretical

Unknown Theoretical

Diltiazem - increases exposure

Miconazole is predicted to increase the exposure to calcium channel blockers (diltiazem).

Unknown Theoretical

Phenindione - increases anticoagulant effect

Miconazolegreatlyincreasestheanticoagulanteffectof phenindione.rTheoretical

Unknown Theoretical

Pimozide - increases exposure

Miconazoleispredictedtoincreasetheexposuretopimozide. Avoid.oTheoretical

Unknown Theoretical

Tobramycin - decreases exposure

Miconazole potentially decreases the exposure to aminoglycosides (tobramycin).

Unknown Anecdotal

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact

Disclaimer: This information is sourced from Pharmacy and Medicines Regulatory Authority (Malawi). Always consult a qualified healthcare professional before using any medication.